Unit of Internal Medicine, Department of Medical & Surgical Sciences, University of Bologna, Italy.
Unit of Oncology, Department of Experimental, Diagnostic & Specialty Medicine, University of Bologna, Italy.
Future Oncol. 2017 Sep;13(21):1893-1905. doi: 10.2217/fon-2017-0166. Epub 2017 Jul 11.
The search for systemic therapies for hepatocellular carcinoma has been characterized by difficulties and failures. Despite recent progresses, many issues are still to be settled. In particular, the development of drugs inhibiting different neoplastic pathways remains a priority for patients intolerant or resistant to antiangiogenic drugs. This task may be daunting, as previous failures extensively demonstrated. We aimed to identify the future perspective of postsorafenib trials analyzing the strengths and the critical points of past and currently undergoing studies, in the light of the most recent evidences in the field. We identified various points (including stratification, biomarkers, end points, radiologic criteria of response, treatment beyond radiologic progression) that should be considered by future trials to reduce the risks of failure.
肝细胞癌的系统治疗研究一直充满困难和失败。尽管最近取得了一些进展，但仍有许多问题亟待解决。特别是，对于不能耐受或抵抗抗血管生成药物的患者，开发抑制不同肿瘤途径的药物仍然是当务之急。这一任务可能颇具挑战性，正如之前的失败所广泛证明的那样。我们旨在通过分析过去和正在进行的研究的优势和关键点，结合该领域的最新证据，确定索拉非尼治疗试验的未来前景。我们确定了未来试验应考虑的各种要点（包括分层、生物标志物、终点、影像学反应标准、影像学进展后治疗），以降低失败的风险。
